Eli Lilly Lung Cancer Drug May Succeed Where Avastin Failed
Roche's Avastin is a cancer monolith that generates more than $6 billion in annual sales. But it never worked in squamous cell lung cancer, a form that starts in the lining of the respiratory tract and afflicts a quarter of patients.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Matthew Herper Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Lung Cancer | Pharmaceuticals | Respiratory Medicine | Squamous Cell Carcinoma